{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T18:57:41Z","timestamp":1794769061365,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T00:00:00Z","timestamp":1332288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1756-0500-5-160","type":"journal-article","created":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T17:51:53Z","timestamp":1332438713000},"source":"Crossref","is-referenced-by-count":16,"title":["Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon"],"prefix":"10.1186","volume":"5","author":[{"given":"J\u00fcrgen","family":"Noeske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Voelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Fon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Abena Foe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,21]]},"reference":[{"key":"1475_CR1","volume-title":"Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO Progress Report 2011","author":"World Health Organization","year":"2011","unstructured":"World Health Organization: Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO Progress Report 2011. 2011, Geneva: WHO, WHO\/HTM\/TB\/2011.3"},{"key":"1475_CR2","unstructured":"World Health Organization: Global Tuberculosis Control 2010. - accessed December 2010, [\n                    http:\/\/www.who.int\/tb\/publications\/global_report\/2010\/en\/index.html\n                    \n                  ]"},{"key":"1475_CR3","volume-title":"Guidelines for Surveillance of Drug Resistance in Tuberculosis","author":"World Health Organization","year":"2009","unstructured":"World Health Organization: Guidelines for Surveillance of Drug Resistance in Tuberculosis. 2009, Geneva: WHO, WHO\/HTM\/TB\/2009.422, 4","edition":"4"},{"key":"1475_CR4","volume-title":"Global Plan to Stop TB 2006-2015","author":"World Health Organization","year":"2006","unstructured":"World Health Organization: Global Plan to Stop TB 2006-2015. 2006, Geneva: WHO, (WHO\/HTM\/STB\/2006.35)"},{"key":"1475_CR5","volume-title":"Treatment of tuberculosis: guidelines","author":"World Health Organization","year":"2010","unstructured":"World Health Organization: Treatment of tuberculosis: guidelines. 2010, Geneva: WHO, WHO\/HTM\/TB\/2009.420, 4","edition":"4"},{"key":"1475_CR6","first-page":"S193","volume":"12","author":"C Kuaban","year":"2009","unstructured":"Kuaban C, Noeske J, Nyankiye E, Piubello , Eyangoh S: Experience with a 21-month standardized regimen for the treatment of multidrug-resistant tuberculosis in Cameroon. Int J Tuberc Lung Dis. 2009, 12: S193-PC-94308-06","journal-title":"Int J Tuberc Lung Dis"},{"issue":"Suppl3","key":"1475_CR7","first-page":"S192","volume":"15","author":"C Kuaban","year":"2011","unstructured":"Kuaban C, Noeske J, Abena JL, Ait-Khaled N, Rieder H, Tr\u00e9bucq A: Preliminary outcomes of a 12-month standardized regimen for the treatment of multidrug-resistant tuberculosis in Cameroon. Int J Tuberc Lung Dis. 2011, 15 (Suppl3): S192-","journal-title":"Int J Tuberc Lung Dis"},{"key":"1475_CR8","first-page":"217","volume":"27","author":"G Canetti","year":"1963","unstructured":"Canetti G, Rist N, Grosset J: Mesure de la sensibilit\u00e9 du bacille tuberculeux aux drogues antibacillaires par la m\u00e9thode des proportions. RevTuberc Pneumol. 1963, 27: 217-272.","journal-title":"RevTuberc Pneumol"},{"key":"1475_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1471-2334-11-94","volume":"11","author":"J-P Assam-Assam","year":"2011","unstructured":"Assam-Assam J-P, Penlap VB, Cho-Ngwa F, Tedom J-C, Ane-Anyangwe I, Titanji V-P: Mycobacterium tuberculosis complex drug resistance pattern and identification of species causing tuberculosis in the West and Centre regions of Cameroon. BMC Infect Dis. 2011, 11: 94-10.1186\/1471-2334-11-94.","journal-title":"BMC Infect Dis"},{"key":"1475_CR10","volume-title":"Identification of MDR-TB in Retreatment Cases in Cameroon and Benin. A preliminary evaluation [abstract]","author":"J Noeske","year":"2009","unstructured":"Noeske J, Kuaban C, Nkamsse P, Fon E: Identification of MDR-TB in Retreatment Cases in Cameroon and Benin. A preliminary evaluation [abstract]. 2009, Ouagadougou: Union Conference African Region: A-92252, 17","edition":"17"},{"key":"1475_CR11","volume-title":"MDR-TB surveillance under programme conditions in Cameroon: feasibility, constraints, and results [abstract]","author":"J Noeske","year":"2011","unstructured":"Noeske J, Kuaban C, Sander M: MDR-TB surveillance under programme conditions in Cameroon: feasibility, constraints, and results [abstract]. 2011, Abuja: Union Conference African Region: A40-3-3-2011, 18","edition":"18"},{"key":"1475_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0035-9203(02)90383-4","volume":"96","author":"J Noeske","year":"2002","unstructured":"Noeske J, Nguenko PN: Impact of resistance to anti-tuberculosis drugs on treatment outcome using World Health Organization standard regimens. Trans R Soc Trop Med Hyg. 2002, 96: 429-433. 10.1016\/S0035-9203(02)90383-4.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1475_CR13","doi-asserted-by":"publisher","first-page":"e5561","DOI":"10.1371\/journal.pone.0005561","volume":"4","author":"S Suchindran","year":"2009","unstructured":"Suchindran S, Brouwer ES, Van Rie A: Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic Review. PLoS ONE. 2009, 4: e5561-10.1371\/journal.pone.0005561.","journal-title":"PLoS ONE"},{"key":"1475_CR14","doi-asserted-by":"publisher","first-page":"e1000421","DOI":"10.1371\/journal.pmed.1000421","volume":"8","author":"JA Singh","year":"2011","unstructured":"Singh JA: The Challenge of Discharging Research Ethics Duties in Resource-Constrained Settings. PLoS Med. 2011, 8: e1000421-10.1371\/journal.pmed.1000421.","journal-title":"PLoS Med"},{"key":"1475_CR15","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1378\/chest.111.5.1162","volume":"111","author":"AL Kritski","year":"1997","unstructured":"Kritski AL, Rodrigues de Jesus, Andrade MK, Werneck-Barroso E, Vieira MA, Haffner A, Riley LW: Retreatment Tuberculosis Cases: Factors Associated With Drug Resistance and Adverse Outcomes. Chest. 1997, 111: 1162-1167. 10.1378\/chest.111.5.1162.","journal-title":"Chest"},{"key":"1475_CR16","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1001\/jama.283.19.2537","volume":"283","author":"MA Espinal","year":"2000","unstructured":"Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Ba\u00e9z J, Kochi A, Dye C, Raviglione MC: Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis. Jama. 2000, 283: 2537-2545. 10.1001\/jama.283.19.2537.","journal-title":"Jama"},{"key":"1475_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1164\/rccm.200802-240OC","volume":"178","author":"A Mak","year":"2008","unstructured":"Mak A, Thomas A, del Granado M, Zaleskis R, Mouzafarova N, Menzies D: Influence of Multidrug Resistance on Tuberculosis Outcomes with Standardized Regimes. Am J Respir Crit Care Med. 2008, 178: 306-312. 10.1164\/rccm.200802-240OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1475_CR18","doi-asserted-by":"publisher","first-page":"e7954","DOI":"10.1371\/journal.pone.0007954","volume":"4","author":"F Matthys","year":"2009","unstructured":"Matthys F, Rigouts L, Sizaire V, Vezhnina N, Lecoq M, Golubeva V, Portaels F, Van der Stuyft P, Kimerling M: Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. PLoS One. 2009, 4: e7954-10.1371\/journal.pone.0007954.","journal-title":"PLoS One"},{"key":"1475_CR19","first-page":"7","volume":"28","author":"E Green","year":"2010","unstructured":"Green E, Obi CL, Nchabeleng M, de Villiers BE, Sein PP, Letsoalo T, Hoosen AA, Bessong PO, Ndip RN: Drug-susceptibility patterns of Mycobacterium tuberculosis in Mpumalanga province, South Africa: possible guiding design of retreatment regimen. J Health Popul Nutr. 2010, 28: 7-13.","journal-title":"J Health Popul Nutr"},{"key":"1475_CR20","doi-asserted-by":"publisher","first-page":"e10799","DOI":"10.1371\/journal.pone.0010799","volume":"5","author":"GX He","year":"2010","unstructured":"He GX, Xie YG, Wang LX, Borgdorff MW, van der Werf MJ, Fan JH, Yan XL, Li FB, Zhang XZ, Zhao YL, van den Hof S: Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. PLoS One. 2010, 5: e10799-10.1371\/journal.pone.0010799.","journal-title":"PLoS One"},{"key":"1475_CR21","first-page":"e1000427","volume":"8","author":"EC Jones-Lopez","year":"2011","unstructured":"Jones-Lopez EC, Ayakaka I, Levin J, Reilly N, Mumbowa F, Dryden-Peterson S, Nyakoojo G, Fennelly K, Temple B, Nakubulwa S, Joloba ML, Okwera A, Eisenach KD, McNerney R, Elliott AM, Ellner JJ, Smith PG, Mugerwa RD: Effectiveness of the Standard WHO Recommended Retreatment Regimen (Category II) for Tuberculosis in Kampala. Uganda: A Prospective Cohort Study. PLoS Med. 2011, 8: e1000427-","journal-title":"Uganda: A Prospective Cohort Study. PLoS Med"},{"key":"1475_CR22","first-page":"631","volume":"7","author":"HT Quy","year":"2003","unstructured":"Quy HT, Lan NT, Borgdorff MW, Grosset J, Linh PD, Tung LB, van Soolingen D, Raviglione M, C\u00f4 NV, Broekmans J: Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate?. Int J Tuberc Lung Dis. 2003, 7: 631-636.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1475_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.socscimed.2004.08.046","volume":"61","author":"JY Kim","year":"2005","unstructured":"Kim JY, Shakow A, Mate K, Vandervarker C, Gupta R, Farmer P: Limited good and limited vision: multidrug-resistant tuberculosis and global health policy. Soc Sci Med. 2005, 61: 847-859. 10.1016\/j.socscimed.2004.08.046.","journal-title":"Soc Sci Med"},{"key":"1475_CR24","first-page":"23","volume":"8","author":"A Van Deun","year":"2004","unstructured":"Van Deun A, Salim AH, Daru P, Das AP, Aung KJ, Hossain MA, Rigouts L, Fissette K, Portaels F: Drug resistance monitoring: combined rates may be the best indicator for programme performance. Int J Tuberc Lung Dis. 2004, 8: 23-30.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1475_CR25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/cid\/cir081","volume":"52","author":"M Zignol","year":"2011","unstructured":"Zignol M, van Gemert W, Falzon D, Jaramillo E, Blanc L, Raviglione M: Modernizing Surveillance of Antituberculosis Drug Resistance: From Special Surveys to Routine Testing. Clin Infect Dis. 2011, 52: 901-906. 10.1093\/cid\/cir081.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-5-160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-0500-5-160\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-5-160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T02:42:40Z","timestamp":1548124960000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-5-160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,21]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1475"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-5-160","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,21]]},"article-number":"160"}}